SEPN
Septerna, Inc.
NASDAQ · Healthcare · Biotechnology · US
$38.69
−2.05%Next report
Analyst consensus
- Next report date
- Nov 9, 2026
- EPS estimate
- -$0.41
- Revenue estimate
- $20.8M
Latest reported
- Last report date
- Aug 10, 2026
- EPS actual
- -$0.29
- EPS estimate
- -$0.43
- Revenue actual
- $26.7M
- Revenue estimate
- $19.2M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 4
- EPS misses (12Q)
- 2
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +17.8%
- Revenue beats (12Q)
- 3
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $52
- PT range
- $43 – $62
- Analysts
- 6
6 Buy0 Hold0 Sell
No earnings call summaries available
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 10, 2026 | -$0.43 | -$0.29 | Beat 31.92% | $26.7M |
| May 12, 2026 | -$0.51 | -$0.19 | Beat 62.75% | $26.5M |
| Mar 9, 2026 | -$0.25 | -$0.24 | Beat 5.63% | $24.1M |
| May 15, 2025 | -$0.38 | -$0.49 | Miss -28.95% | — |
| Mar 27, 2025 | -$0.69 | -$0.64 | Beat 7.25% | $212.0K |
| Nov 20, 2024 | -$0.83 | -$8.40 | Miss -912.05% | $176.0K |
| Dec 31, 2023 | — | $2.05 | — | $118.0K |
| Sep 30, 2023 | — | -$0.56 | — | $33.0K |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 9, 2026